Literature DB >> 11078728

Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa.

R J Petrovan1, W Ruf.   

Abstract

Serine protease activation is typically controlled by proteolytic cleavage of the scissile bond, resulting in spontaneous formation of the activating Ile(16)-Asp(194) salt bridge. The initiating coagulation protease factor VIIa (VIIa) differs by remaining in a zymogen-like conformation that confers the control of catalytic activity to the obligatory cofactor and receptor tissue factor (TF). This study demonstrates that the unusual hydrophobic Met(156) residue contributes to the propensity of the VIIa protease domain to remain in a zymogen-like conformation. Mutation of Met(156) to Gln, which is found in the same position of the highly homologous factor IX, had no influence on the amidolytic and proteolytic activity of TF-bound VIIa. Furthermore, the mutation did not appreciably stabilize the labile Ile(16)-Asp(194) salt bridge in the absence of cofactor. VIIa(Gln156) had increased affinity for TF, consistent with a long range conformational effect that stabilized the cofactor binding site in the VIIa protease domain. Notably, in the absence of cofactor, amidolytic and proteolytic function of VIIa(Gln156) were enhanced 3- and 9-fold, respectively, compared with wild-type VIIa. The mutation thus selectively influenced the catalytic activity of free VIIa, identifying the Met(156) residue position as a determinant for the zymogen-like properties of free VIIa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078728     DOI: 10.1074/jbc.M004726200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

Authors:  E Persson; M Kjalke; O H Olsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

2.  Disulfide locked variants of factor VIIa with a restricted beta-strand conformation have enhanced enzymatic activity.

Authors:  Henry R Maun; Charles Eigenbrot; Helga Raab; David Arnott; Lilian Phu; Sherron Bullens; Robert A Lazarus
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

3.  Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.

Authors:  Anders B Sorensen; Inga Tuneew; L Anders Svensson; Egon Persson; Henrik Østergaard; Michael Toft Overgaard; Ole H Olsen; Prafull S Gandhi
Journal:  J Biol Chem       Date:  2019-12-04       Impact factor: 5.157

4.  Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement.

Authors:  Egon Persson; Helle Bak; Anette Østergaard; Ole H Olsen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

5.  Mechanism of the Ca2+-induced enhancement of the intrinsic factor VIIa activity.

Authors:  Jais R Bjelke; Ole H Olsen; Michel Fodje; L Anders Svensson; Susanne Bang; Gert Bolt; Birthe B Kragelund; Egon Persson
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

Review 6.  Structural biology of factor VIIa/tissue factor initiated coagulation.

Authors:  Kanagasabai Vadivel; S Paul Bajaj
Journal:  Front Biosci (Landmark Ed)       Date:  2012-06-01

Review 7.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

8.  Factor VII mutant V154G models a zymogen-like form of factor VIIa.

Authors:  Raffaella Toso; Francesco Bernardi; Theresa Tidd; Mirko Pinotti; Rodney M Camire; Giovanna Marchetti; Katherine A High; Eleanor S Pollak
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.